ArticleThe Journal of allergy and clinical immunology2012
Suppression of the basophil response to allergen during treatment with omalizumab is dependent on 2 competing factors.
Article in The Journal of allergy and clinical immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 59 citations in OpenAlex.
- Mechanistic correlates of clinical responses to omalizumab in the setting of oral immunotherapy for milk allergy.The Journal of allergy and clinical immunology · 2017Trial
- Omalizumab increases the intrinsic sensitivity of human basophils to IgE-mediated stimulation.The Journal of allergy and clinical immunology · 2013Trial
- Emerging Biomarkers in Pediatric Food Allergy: From Mechanistic Endotyping to Precision Diagnosis and Therapeutic Monitoring.Biomedicines · 2026Review
- Oral Food Challenges After Treatment With Omalizumab in the Clinical Setting.The journal of allergy and clinical immunology. In practice · 2026Article
- Recent Advances and New Therapeutic Goals in the Management of Severe Asthma.Internal medicine (Tokyo, Japan) · 2026Review
- Basophil Activation Test in IgE-Mediated Wheat Allergy: Diagnostic and Clinical Applications-A Narrative Review.Diagnostics (Basel, Switzerland) · 2025Review
- Biologics and airway remodeling in severe asthma.Allergy · 2022Review
- Combining Anti-IgE Monoclonal Antibodies and Oral Immunotherapy for the Treatment of Food Allergy.Clinical reviews in allergy & immunology · 2022Review
- The Potential Role of Basophils in Urticaria.Frontiers in immunology · 2022Review
- Autoantibodies to IgE and FcεRI and the natural variability of spleen tyrosine kinase expression in basophils.The Journal of allergy and clinical immunology · 2019Article
- Basophil Activation Test: Old and New Applications in Allergy.Current allergy and asthma reports · 2018Review
- The Use of Biomarkers to Predict Aero-Allergen and Food Immunotherapy Responses.Clinical reviews in allergy & immunology · 2018Review
- Two decades with omalizumab: what we still have to learn.Biologics : targets & therapy · 2018Review
- Road map for the clinical application of the basophil activation test in food allergy.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2017Review
- Mechanisms of action that contribute to efficacy of omalizumab in chronic spontaneous urticaria.Allergy · 2017Review
- Article
- Stability of Syk protein and mRNA in human peripheral blood basophils.Journal of leukocyte biology · 2016Article
- Pros and Cons of Clinical Basophil Testing (BAT).Current allergy and asthma reports · 2016Review
- Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.Nature communications · 2016Article
- Cytomegalic hepatitis in a patient receiving omalizumab.IDCases · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundA recent study of subjects with peanut allergy treated with omalizumab generated some results that were concordant with a study of subjects with cat allergy treated with omalizumab. However, there were differences that provided additional insight into the nature of the cellular responses in allergic subjects.
objectiveWe sought to determine the cause for failure to suppress the allergen-induced basophil response during treatment with omalizumab.
methodsPatients with peanut allergy were treated with omalizumab. Clinical, serologic, and cellular indices relevant to the response of the subjects and their peripheral blood basophil values (specific/total IgE ratio, cell-surface FcεRI expression, and histamine release responses to anti-IgE antibody or peanut allergen) were obtained at 3 times.
resultsAfter treatment, approximately 60% of the subjects' basophil responses to peanut allergen did not significantly decrease. In 40% of cases, the in vitro basophil response to peanut allergen increased 2- to 7-fold. The increases were associated with 2 primary factors: a high (>10%) specific/total IgE ratio and an increase in the intrinsic response of the basophil to IgE-mediated stimulation. The extent to which the basophil response to peanut allergen increased was inversely correlated with improvement in the patient's ability to tolerate ingestion of peanut.
conclusionThe basophil response during treatment with omalizumab is a consequence of 2 competing factors: suppression of allergen-specific IgE on the cell surface versus increased intrinsic sensitivity to IgE-mediated stimulation. In subjects with peanut allergy, the basophil response appears to mitigate against the ability of omalizumab to improve the patient's tolerance of oral allergen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.